Alzheimer’s Disease
Conditions
Interventions
None listed
Sponsors
Alnylam Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Outcome results
None listed
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Feb 11, 2026